Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas F Patterson

Showing results (171-180 of 204) with videos related to

Pageof 21
Sort By:
Frontiers in Immunology|March 27, 2023
Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiativeHector Bonilla, Michael J Peluso, Kathleen Rodgers, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 5, 2006
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trialThomas J Walsh, Issam Raad, Thomas F Patterson, et al.
The New England Journal of Medicine|August 9, 2002
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosisRaoul Herbrecht, David W Denning, Thomas F Patterson, et al.
Journal of General Internal Medicine|January 13, 2025
Incidence and Prevalence of Post-COVID-19 Myalgic Encephalomyelitis: A Report from the Observational RECOVER-Adult StudySuzanne D Vernon, Tianyu Zheng, Hyungrok Do, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 12, 2010
Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)Peter G Pappas, Barbara D Alexander, David R Andes, et al.
The European Respiratory Journal|March 3, 2022
Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statementEva Van Braeckel, Iain Page, Jesper Rømhild Davidsen, et al.
Emerging Infectious Diseases|October 18, 2011
Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006Benjamin J Park, Peter G Pappas, Kathleen A Wannemuehler, et al.
Lancet (London, England)|December 20, 2015
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trialJohan A Maertens, Issam I Raad, Kieren A Marr, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 12, 2010
Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) DatabaseDimitrios P Kontoyiannis, Kieren A Marr, Benjamin J Park, et al.
Intensive Care Medicine|June 23, 2021
Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosisPaul E Verweij, Roger J M Brüggemann, Elie Azoulay, et al.
Pageof 21

Showing results (171-180 of 204) with videos related to

Sort By:
Pageof 21
Frontiers in Immunology|March 27, 2023
Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiativeHector Bonilla, Michael J Peluso, Kathleen Rodgers, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 5, 2006
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trialThomas J Walsh, Issam Raad, Thomas F Patterson, et al.
The New England Journal of Medicine|August 9, 2002
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosisRaoul Herbrecht, David W Denning, Thomas F Patterson, et al.
Journal of General Internal Medicine|January 13, 2025
Incidence and Prevalence of Post-COVID-19 Myalgic Encephalomyelitis: A Report from the Observational RECOVER-Adult StudySuzanne D Vernon, Tianyu Zheng, Hyungrok Do, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 12, 2010
Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)Peter G Pappas, Barbara D Alexander, David R Andes, et al.
The European Respiratory Journal|March 3, 2022
Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statementEva Van Braeckel, Iain Page, Jesper Rømhild Davidsen, et al.
Emerging Infectious Diseases|October 18, 2011
Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006Benjamin J Park, Peter G Pappas, Kathleen A Wannemuehler, et al.
Lancet (London, England)|December 20, 2015
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trialJohan A Maertens, Issam I Raad, Kieren A Marr, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 12, 2010
Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) DatabaseDimitrios P Kontoyiannis, Kieren A Marr, Benjamin J Park, et al.
Intensive Care Medicine|June 23, 2021
Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosisPaul E Verweij, Roger J M Brüggemann, Elie Azoulay, et al.
Pageof 21